GILEAD SCIENCES, INC. (GILD) FY2025 Q1 P&L / Income Statement

Income StatementCash FlowBalance Sheet

Revenue by Product and Service by Geography

2025-01-01 to 2025-03-31

Swipe to see the full flow
GILEAD SCIENCES, INC. (GILD) FY2025 Q1 P&L / Income StatementIncome statement for 2025-01-01 through 2025-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETProduct sales - UNITED STATESTotal HIV - UNITED STATESBiktarvy - UNITED STATESProduct sales - EuropeProduct sales - Rest of WorldTotal HIV - EuropeDescovy - UNITED STATESTotal Oncology - UNITED STATESBiktarvy - EuropeTotal HIV - Rest of WorldTotal Liver Disease - UNITED STATESGenvoya - UNITED STATESBiktarvy - Rest of WorldTotal Liver Disease - Rest of WorldTotal Oncology - EuropeOdefsey - UNITED STATESTotal Cell Therapy - UNITED STATESVeklury - UNITED STATESTrodelvy - UNITED STATESTotal Cell Therapy - EuropeTotal Liver Disease - EuropeSofosbuvir/Velpatasvir - UNITED STATESYescarta - UNITED STATESYescarta - EuropeVemlidy - Rest of WorldTotal Oncology - Rest of WorldVemlidy - UNITED STATESSofosbuvir/Velpatasvir - Rest of WorldTotal Cell Therapy - Rest of WorldSymtuza - Revenue share - UNITED STATESVeklury - Rest of WorldTotal Other - Rest of WorldSofosbuvir/Velpatasvir - EuropeYescarta - Rest of WorldTotal Other - EuropeTrodelvy - EuropeAmBisome - EuropeAmBisome - Rest of WorldOdefsey - EuropeTotal Other - UNITED STATESTecartus - UNITED STATESGenvoya - EuropeRoyalty, contract and other revenues - UNITED STATESTrodelvy - Rest of WorldTecartus - EuropeSymtuza - Revenue share - EuropeDescovy - Rest of WorldVeklury - EuropeDescovy - EuropeGenvoya - Rest of WorldVemlidy - EuropeRoyalty, contract and other revenues - EuropeOdefsey - Rest of WorldTecartus - Rest of WorldRoyalty, contract and other revenues - Rest of WorldAmBisome - UNITED STATESSymtuza - Revenue share - Rest of WorldOther Liver Disease - EuropeOther Liver Disease - UNITED STATESOther HIV - UNITED STATESOther - UNITED STATESOther HIV - EuropeOther Liver Disease - Rest of WorldOther - Rest of WorldOther HIV - Rest of WorldOther - EuropeTotal revenuesRevenue before reconciliation (calculated)Components above reported revenue (calculated)Gross profit (calculated)Cost of goods soldOperating income (loss)Operating expenses (calculated)Research and development expensesSelling, general and administrative expensesAcquired in-process research and development expensesIncome (loss) before income taxesOther income (expense), net (calculated)Net income (loss)Income tax expense (benefit)Revenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$20.06 BGross profit (calculated)Gross profit(calculated)$5.13 BOperating income (loss)Operatingincome (loss)$2.24 BIncome (loss) before income taxesIncome (loss)before income taxes$1.65 BTotal revenuesTotal revenues$6.67 BNet income (loss)Net income (loss)$1.32 BProduct sales - UNITED STATESProduct sales -UNITED STATES$4.63 BOperating expenses (calculated)Operating expenses(calculated)$2.89 BIncome tax expense (benefit)Income taxexpense (benefit)$334.00 MTotal HIV - UNITED STATESTotal HIV -UNITED STATES$3.66 BCost of goods soldCost of goods sold$1.54 BResearch and development expensesResearch anddevelopment expenses$1.38 BOther income (expense), net (calculated)Other income,net (calculated)−$588.00 MBiktarvy - UNITED STATESBiktarvy -UNITED STATES$2.47 BSelling, general and administrative expensesSelling, general andadministrative expenses$1.26 BProduct sales - EuropeProduct sales - Europe$1.07 BAcquired in-process research and development expensesAcquired in-process researchand development expenses$253.00 MProduct sales - Rest of WorldProduct sales- Rest of World$909.00 MTotal HIV - EuropeTotal HIV - Europe$553.00 MComponents above reported revenue (calculated)Components abovereported revenue(calculated)−$13.39 BDescovy - UNITED STATESDescovy -UNITED STATES$538.00 MTotal Oncology - UNITED STATESTotal Oncology- UNITED STATES$381.00 MBiktarvy - EuropeBiktarvy - Europe$375.00 MTotal HIV - Rest of WorldTotal HIV -Rest of World$370.00 MTotal Liver Disease - UNITED STATESTotal Liver Disease- UNITED STATES$335.00 MGenvoya - UNITED STATESGenvoya -UNITED STATES$305.00 MBiktarvy - Rest of WorldBiktarvy - Rest of World$301.00 MTotal Liver Disease - Rest of WorldTotal Liver Disease- Rest of World$256.00 MTotal Oncology - EuropeTotal Oncology- Europe$255.00 MOdefsey - UNITED STATESOdefsey -UNITED STATES$215.00 MTotal Cell Therapy - UNITED STATESTotal Cell Therapy- UNITED STATES$200.00 MVeklury - UNITED STATESVeklury -UNITED STATES$199.00 MTrodelvy - UNITED STATESTrodelvy -UNITED STATES$181.00 MTotal Cell Therapy - EuropeTotal CellTherapy - Europe$180.00 MTotal Liver Disease - EuropeTotal LiverDisease - Europe$168.00 MSofosbuvir/Velpatasvir - UNITED STATESSofosbuvir/Velpatasvir- UNITED STATES$166.00 MYescarta - UNITED STATESYescarta -UNITED STATES$160.00 MYescarta - EuropeYescarta - Europe$149.00 MVemlidy - Rest of WorldVemlidy - Rest of World$140.00 MTotal Oncology - Rest of WorldTotal Oncology- Rest of World$121.00 MVemlidy - UNITED STATESVemlidy -UNITED STATES$100.00 MSofosbuvir/Velpatasvir - Rest of WorldSofosbuvir/Velpatasvir- Rest of World$99.00 MTotal Cell Therapy - Rest of WorldTotal Cell Therapy- Rest of World$84.00 MSymtuza - Revenue share - UNITED STATESSymtuza - Revenueshare - UNITED STATES$82.00 MVeklury - Rest of WorldVeklury - Rest of World$82.00 MTotal Other - Rest of WorldTotal Other -Rest of World$81.00 MSofosbuvir/Velpatasvir - EuropeSofosbuvir/Velpatasvir- Europe$80.00 MYescarta - Rest of WorldYescarta -Rest of World$77.00 MTotal Other - EuropeTotal Other - Europe$76.00 MTrodelvy - EuropeTrodelvy - Europe$75.00 MAmBisome - EuropeAmBisome - Europe$67.00 MAmBisome - Rest of WorldAmBisome -Rest of World$66.00 MOdefsey - EuropeOdefsey - Europe$57.00 MTotal Other - UNITED STATESTotal Other -UNITED STATES$52.00 MTecartus - UNITED STATESTecartus -UNITED STATES$40.00 MGenvoya - EuropeGenvoya - Europe$40.00 MRoyalty, contract and other revenues - UNITED STATESRoyalty, contractand other revenues- UNITED STATES$37.00 MTrodelvy - Rest of WorldTrodelvy -Rest of World$37.00 MTecartus - EuropeTecartus - Europe$31.00 MSymtuza - Revenue share - EuropeSymtuza - Revenueshare - Europe$29.00 MDescovy - Rest of WorldDescovy -Rest of World$27.00 MVeklury - EuropeVeklury - Europe$22.00 MDescovy - EuropeDescovy - Europe$21.00 MGenvoya - Rest of WorldGenvoya -Rest of World$19.00 MVemlidy - EuropeVemlidy - Europe$12.00 MRoyalty, contract and other revenues - EuropeRoyalty, contractand otherrevenues - Europe$11.00 MOdefsey - Rest of WorldOdefsey - Rest of World$10.00 MTecartus - Rest of WorldTecartus -Rest of World$8.00 MRoyalty, contract and other revenues - Rest of WorldRoyalty, contractand other revenues- Rest of World$6.00 MAmBisome - UNITED STATESAmBisome -UNITED STATES$5.00 MSymtuza - Revenue share - Rest of WorldSymtuza - Revenueshare - Rest of World$3.00 MOther Liver Disease - EuropeOther LiverDisease - Europe$76.00 MOther Liver Disease - UNITED STATESOther Liver Disease- UNITED STATES$68.00 MOther HIV - UNITED STATESOther HIV -UNITED STATES$50.00 MOther - UNITED STATESOther - UNITED STATES$47.00 MOther HIV - EuropeOther HIV - Europe$31.00 MOther Liver Disease - Rest of WorldOther Liver Disease- Rest of World$17.00 MOther - Rest of WorldOther - Rest of World$14.00 MOther HIV - Rest of WorldOther HIV -Rest of World$10.00 MOther - EuropeOther - Europe$9.00 M
Chart details

GILEAD SCIENCES, INC. (GILD) FY2025 Q1 P&L / Income Statement

Income statement for 2025-01-01 through 2025-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues
6,667,000,000 US dollars
Cost of goods sold
1,540,000,000 US dollars
Gross profit (calculated)
5,127,000,000 US dollars
Operating expenses (calculated)
2,890,000,000 US dollars
Operating income (loss)
2,237,000,000 US dollars
Other income (expense), net (calculated)
negative 588,000,000 US dollars
Income (loss) before income taxes
1,649,000,000 US dollars
Income tax expense (benefit)
334,000,000 US dollars
Net income (loss)
1,315,000,000 US dollars
Tecartus - UNITED STATES
40,000,000 US dollars
Tecartus - Rest of World
8,000,000 US dollars
Tecartus - Europe
31,000,000 US dollars
Total Cell Therapy - UNITED STATES
200,000,000 US dollars
Total Cell Therapy - Rest of World
84,000,000 US dollars
Total Cell Therapy - Europe
180,000,000 US dollars
Total HIV - UNITED STATES
3,664,000,000 US dollars
Total HIV - Rest of World
370,000,000 US dollars
Total HIV - Europe
553,000,000 US dollars
Biktarvy - UNITED STATES
2,474,000,000 US dollars
Biktarvy - Rest of World
301,000,000 US dollars
Biktarvy - Europe
375,000,000 US dollars
Descovy - UNITED STATES
538,000,000 US dollars
Descovy - Rest of World
27,000,000 US dollars
Descovy - Europe
21,000,000 US dollars
Genvoya - UNITED STATES
305,000,000 US dollars
Genvoya - Rest of World
19,000,000 US dollars
Genvoya - Europe
40,000,000 US dollars
Odefsey - UNITED STATES
215,000,000 US dollars
Odefsey - Rest of World
10,000,000 US dollars
Odefsey - Europe
57,000,000 US dollars
Other HIV - UNITED STATES
50,000,000 US dollars
Other HIV - Rest of World
10,000,000 US dollars
Other HIV - Europe
31,000,000 US dollars
Symtuza - Revenue share - UNITED STATES
82,000,000 US dollars
Symtuza - Revenue share - Rest of World
3,000,000 US dollars
Symtuza - Revenue share - Europe
29,000,000 US dollars
Total Liver Disease - UNITED STATES
335,000,000 US dollars
Total Liver Disease - Rest of World
256,000,000 US dollars
Total Liver Disease - Europe
168,000,000 US dollars
Other Liver Disease - UNITED STATES
68,000,000 US dollars
Other Liver Disease - Rest of World
17,000,000 US dollars
Other Liver Disease - Europe
76,000,000 US dollars
Sofosbuvir/Velpatasvir - UNITED STATES
166,000,000 US dollars
Sofosbuvir/Velpatasvir - Rest of World
99,000,000 US dollars
Sofosbuvir/Velpatasvir - Europe
80,000,000 US dollars
Vemlidy - UNITED STATES
100,000,000 US dollars
Vemlidy - Rest of World
140,000,000 US dollars
Vemlidy - Europe
12,000,000 US dollars
Total Oncology - UNITED STATES
381,000,000 US dollars
Total Oncology - Rest of World
121,000,000 US dollars
Total Oncology - Europe
255,000,000 US dollars
AmBisome - UNITED STATES
5,000,000 US dollars
AmBisome - Rest of World
66,000,000 US dollars
AmBisome - Europe
67,000,000 US dollars
Other - UNITED STATES
47,000,000 US dollars
Other - Rest of World
14,000,000 US dollars
Other - Europe
9,000,000 US dollars
Total Other - UNITED STATES
52,000,000 US dollars
Total Other - Rest of World
81,000,000 US dollars
Total Other - Europe
76,000,000 US dollars
Yescarta - UNITED STATES
160,000,000 US dollars
Yescarta - Rest of World
77,000,000 US dollars
Yescarta - Europe
149,000,000 US dollars
Royalty, contract and other revenues - UNITED STATES
37,000,000 US dollars
Royalty, contract and other revenues - Rest of World
6,000,000 US dollars
Royalty, contract and other revenues - Europe
11,000,000 US dollars
Trodelvy - UNITED STATES
181,000,000 US dollars
Trodelvy - Rest of World
37,000,000 US dollars
Trodelvy - Europe
75,000,000 US dollars
Veklury - UNITED STATES
199,000,000 US dollars
Veklury - Rest of World
82,000,000 US dollars
Veklury - Europe
22,000,000 US dollars
Product sales - UNITED STATES
4,631,000,000 US dollars
Product sales - Rest of World
909,000,000 US dollars
Product sales - Europe
1,073,000,000 US dollars
Selling, general and administrative expenses
1,258,000,000 US dollars
Acquired in-process research and development expenses
253,000,000 US dollars
Research and development expenses
1,379,000,000 US dollars
In-process research and development impairments
0 US dollars
Revenue before reconciliation (calculated)
20,057,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Components above reported revenue (calculated)
negative 13,390,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
GILEAD SCIENCES, INC. (GILD) FY2025 Q1 P&L / Income Statement Sankey chart, Product and service — Product and Service by Geographical view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

76.9%

Gross profit / revenue

Operating margin

33.6%

Operating profit / revenue

Cash conversion

133.6%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!